CAA | Boston Medical Center
BMC Updates and Information.

BMC is seeing patients at our hospital and clinics—see how we’re keeping everyone safe. Book your next appointment today or learn about our telehealth options.

To protect the health of patients and staff, BMC is restricting all visitors unless pre-approved by each patient's care team under extenuating circumstances.

Community vaccine sites are now open for booking appointments for Boston residents

doctor Find a doctor


CAA: A phase 2 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ponezumab in adult subjects with probable Cerebral Amyloid Angiopathy

Sponsor: Pfizer

Investigators: Carlos Kase MD (principal), Viken Babikian MD, Thanh Nguyen MD, Jose Romero MD, Hesham Masoud MD, Hugo Aparicio MD


Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain. Probable CAA may be defined as two or more hemorrhages in the brain cortex in individuals 55 years of age or older. This study will examine the study drug (PF-04360365) vs. placebo (saline) at 10 mg/kg - Day 1 and the maintenance dose of the study drug (PF-04360365) vs. placebo (saline) at 7.5mg/kg on Days 30 and 60. Subjects will be followed for 6 months after receiving the last dose of study medication.

Results pending